An Intra-Cellular Therapies Inc. patent describes new 5-HT2A, μ-opioid, and dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.

Alumis Inc. has patented non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, neurological, autoimmune, inflammatory and endocrine disorders.

In accordance with the publishing schedule, BioWorld Science will not be published on Thursday, Oct. 12, 2023.

It has been previously demonstrated that therapeutic inhibition of the prostaglandin E2 (PGE2)-degrading enzyme, 15-prostaglandin dehydrogenase (15-PGDH), was able to improve muscle strength in aged mice. Researchers from Epirium Bio Inc. have now reported the discovery and preclinical characterization an orally bioavailable small molecule inhibitor of 15-PGDH – MF-300 – being developed for the treatment of neuromuscular dysfunction.